Media coverage about Hill-Rom (NYSE:HRC) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hill-Rom earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned media headlines about the medical technology company an impact score of 48.0474809243241 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Hill-Rom Holdings (HRC) to Divest Third-Party Rental Business (streetinsider.com)
- Hill-Rom Announces Divestiture Of Third-Party Rental Business (finance.yahoo.com)
- Hospital Beds Global Market Prognosticated To Perceive A Thriving Growth MRFR Unleashes Industry Insights Up To 2023 (menafn.com)
- Hill-Rom taps Imprivata to secure Welch Allyn Connex monitor data (massdevice.com)
- Zacks: Analysts Expect Hill-Rom Holdings, Inc. (HRC) Will Post Quarterly Sales of $709.03 Million (americanbankingnews.com)
Shares of Hill-Rom (NYSE:HRC) traded down $0.49 on Wednesday, reaching $87.26. The company’s stock had a trading volume of 164,630 shares, compared to its average volume of 549,265. Hill-Rom has a 12-month low of $68.03 and a 12-month high of $91.11. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.29 and a current ratio of 1.75. The company has a market capitalization of $5,812.04, a PE ratio of 29.70, a P/E/G ratio of 1.41 and a beta of 1.03.
Hill-Rom (NYSE:HRC) last announced its earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.13. Hill-Rom had a return on equity of 20.24% and a net margin of 7.14%. The business had revenue of $669.70 million for the quarter, compared to analyst estimates of $670.00 million. During the same quarter last year, the firm earned $0.75 EPS. Hill-Rom’s revenue for the quarter was up 5.1% compared to the same quarter last year. equities analysts expect that Hill-Rom will post 4.62 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 23rd will be given a dividend of $0.20 per share. This is a positive change from Hill-Rom’s previous quarterly dividend of $0.18. The ex-dividend date is Thursday, March 22nd. This represents a $0.80 annualized dividend and a dividend yield of 0.92%. Hill-Rom’s payout ratio is 24.49%.
HRC has been the subject of a number of recent analyst reports. ValuEngine cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Raymond James Financial raised Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 target price for the company in a research report on Wednesday, January 3rd. Needham & Company LLC reiterated a “buy” rating on shares of Hill-Rom in a research note on Friday, January 26th. Finally, KeyCorp restated a “buy” rating and issued a $97.00 target price on shares of Hill-Rom in a research note on Thursday, January 18th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $95.38.
In other Hill-Rom news, CEO John J. Greisch sold 125,241 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the transaction, the chief executive officer now owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.90% of the stock is owned by insiders.
Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.